Predictive factors to targeted treatment in gastrointestinal carcinomas

Cancer Biomarkers

Volumn 14, Issue 2-3, 2014, Pages 151-162

  Silvestris, Nicola ^a   Marech, Ilaria ^a   Brunetti, Anna Elisabetta ^a   Azzariti, Amalia ^a   Numico, Gianmauro ^b   Cicero, Giuseppe ^a   Delcuratolo, Sabina ^a   De Luca, Raffaele ^a   Burz, Claudia ^c   Lorusso, Vito ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Ospedale U Parini   (Italy)

^c THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

EGFR; Gastrointestinal cancer; HER2; targeted therapy; VEGF

Indexed keywords

AFLIBERCEPT; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB ALANINATE; CEDIRANIB; CETUXIMAB; DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETHYLENE TETRAHYDROFOLATE REDUCTASE; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RAMUCIRUMAB; REGORAFENIB; SUNITINIB; THYMIDYLATE SYNTHASE; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CHROMOSOME ABERRATION; COLORECTAL CANCER; GASTROINTESTINAL CARCINOMA; GENE DOSAGE; GENE MUTATION; HUMAN; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT PLANNING; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GASTROINTESTINAL NEOPLASMS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; STOMACH NEOPLASMS;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICROSATELLITE INSTABILITY; MOLECULAR TARGETED THERAPY; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904317949     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130327     Document Type: Article

References (96)

1. A. Abajo, V. Boni, I. Lopez, M. Gonzalez-Huarriz, N. Bitarte, J. Rodriguez et al, Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients, British Journal of Cancer 107 (2012), 287-290.
2. T. Akiyama, C. Sudo, H. Ogawara, K. Toyoshima, T. Yamamoto, The product of the human c-erbB-2 gene: A 185-kilo-Dalton glycoprotein with tyrosine kinase activity, Science 232 (1986), 644-646.
3. H.J. Andreyev, A.R. Norman, D. Cunningham, J.R. Oates, P.A. Clarke, Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study, Journal of National Cancer Institute 90(9) (1998), 675-684.
4. L. Bagnasco, D. Piras, S. Parodi, I. Bauer, G. Zoppoli, F. Patrone et al, Role of angiogenesis inhibitors in colorectal cancer sensitive and in sensitive tumors, Current Cancer Drug Targets 12 (2012), 303-315.
5. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki et al, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial, Lancet 376 (2010), 687-697.
6. M.M. Bertagnolli, D. Niedzwiecki, C.C. Compton, H.P. Hahn, M. Hall, B. Damas et al, Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803, Journal of Clinical Oncology 27(11) (2009), 1814-1821.
7. V. Boige, J. Mendiboure, J.P. Pignon, M.A. Loriot, M. Castaing, M. Barrois et al, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-2005, Journal of Clinical Oncology 28(15) (2010), 2556-2564.
8. C.R. Boland, S.N. Thibodeau, S.R. Hamilton, D. Sidransky, J.R. Eshleman, R.W. Burt et al, A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Research 58(22) (1998), 5248-5257.
9. E. Bria, S. Barbi, G. De Manzoni, et al, Prognostic impact of FHIT, APC, and HER2 status in resected gastric cancer: a clinical-biological risk stratification model, Journal of Clinical Oncology 30s (2012), [Abstract 4076].
10. P. Cejas, M. López-Gómez, C. Aguayo, R. Madero, J. Moreno-Rubio, J. de Castro Carpeño et al, Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy, Current Cancer Drug Targets 12(2) (2012), 124-131.
11. W.H. Chappell, L.S. Steelman, J.M. Long, R.C. Kempf, S.L. Abrams, R.A. Franklin et al, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health, Oncotarget 2(3) (2011), 135-164.
12. KY. Chung, J. Shia, NE. Kemeny, M. Shah, GK. Schwartz, A. Tse et al, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry, Journal of Clinical Oncology 23(9) (2005), 1803-1810.
13. K. Cichowski, PA. Jänne, Drug discovery: inhibitors that activate, Nature 464 (7287) (2010), 358-359.
14. K.H. Cohn, D.L. Ornstein, F. Wang, F.D. LaPaix, K. Phipps, C. Edelsberg et al, The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study, Cancer 79(2) (1997), 233-244.
15. B.C. Danner, J.S. Gerdes, K. Jung, B. Sander, C. Enders, T. Liersch et al, Comparison of chromosomal aberrations in primary colorectal carcinomas to their pulmonary metastases, Cancer Genetics 204(3) (2011), 122-128.
16. W. De Roock, B. Biesmans, J. De Schutter, S. Tejpar, Clinical biomarkers in oncology: Focus on colorectal cancer, Molecular Diagnosis and Therapy 13(2) (2009), 103-114.
17. W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas et al, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis, Lancet Oncology 11(8) (2010), 753-762.
18. W. De Roock, D.J. Jonker, F. Di Nicolantonio, A. Sartore-Bianchi, D. Tu, S. Siena et al, Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab, The Journal of the American Medical Association 304(16) (2010), 1812-1820.
19. L.A. Jr Diaz, R.T. Williams, J. Wu, I. Kinde, J.R. Hecht, J. Berlin et al, The molecular evolution of acquired resis tance to targeted EGFR blockade in colorectal cancers, Nature 486(7404) (2012), 537-540.
20. R. Dienstmann, E. Vilar, J. Tabernero, Molecular predictors of response to chemotherapy in colorectal cancer, The Cancer Journal 17 (2011), 114-126.
21. F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti et al., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, Journal of Clinical Oncology 26(35) (2008), 5705-5712.
22. A. Duffy, S. Kummar, Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors, Target Oncology 4(4) (2009), 267-273.
23. P. Enzinger, D. Ryan, E. Regan, et al, Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer, Journal of Clinical Oncology 26 (2008) Suppl 15: S4552.
24. M.C. Etienne-Grimaldi, G. Milano, F. Maindrault-Goebel, B. Chibaudel, J.L. Formento, M. Francoual et al, Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients, British Journal of Clinical Pharmacology 69(1) (2010), 58-66.
25. A. Fariña-Sarasqueta, G. van Lijnschoten, E. Moerland, G.J. Creemers, V.E. Lemmens, H.J. Rutten et al, The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients, Annals of Oncology 21 (2010), 2396-2402.
26. E.R. Fearon, Molecular genetics of colorectal cancer, Annals of the New York Academy of Sciences 768 (1995), 101-110.
27. G.M. Forbes, Colorectal cancer screening tests: pros and cons, and for whom? Expert Review of Gastroenterology and Hepatology 2 (2) (2008), 197-205.
28. L. Fornaro, M. Lucchesi, C. Caparello, E. Vasile, S. Caponi, L. Ginocchi et al, Anti-HER agents in gastric cancer: From bench to bedside, Nature Reviews Gastroenterology and Hepatology 8 (2011), 369-383.
29. A. Gamboa-Dominguez, C. Dominguez-Fonseca, L. Quintanilla-Martinez, E. Reyes-Gutierrez, D. Green, A. Angeles-Angeles, et al., Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: A multivariate analysis using a standardized immunohistochemical detection system, Modern Pathology 17 (2004), 579-587.
30. M.J. Garnett, R. Marais, Guilty as charged: B-RAF is a human oncogene, Cancer Cell 6(4) (2004), 313-319.
31. S. Gattenlohner, C. Germer, H.K. Muller-Hermelink, K-ras mutations and cetuximab in colorectal cancer, The New England Journal of Medicine 360(8) (2009), 835.
32. B. Glimelius, K. Ekström, K. Hoffman, W. Graf, P.O. Sjödén, U. Haglund, et al, Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer, Annals of Oncology 8 (1997), 163-168.
33. A. Gnoni, A. Russo, N. Silvestris, E. Maiello, A. Vacca, I. Marech, et al, Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients, Current Drug Metabolism 12(10) (2011), 918-931.
34. M.S. Gordon, K. Margolin, M. Talpaz, G.W. Jr Sledge, E. Holmgren, R. Benjamin et al, Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer, Journal of Clinical Oncology 19 (2001), 843-850.
35. C. Gravalos, A. Jimeno, HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target, Annals of Oncology 19 (2008), 1523-1529.
36. A. Grothey, M.M. Sugrue, D.M. Purdie, W. Dong, D. Sargent, E. Hedrick et al, Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE), Journal of Clinical Oncology 26(33) (2008), 5326-5334.
37. S.J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, N. Dhomen et al, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell 140(2) (2010), 209-221.
38. A.C. Hsieh, M.M. Moasser, Targeting HER proteins in cancer therapy and the role of the non-target HER3, British Journal of Cancer 97 (2007), 453-457.
39. S. Iqbal, B. Goldman, C.M. Fenoglio-Preiser, H.J. Lenz, W. Zhang, K.D. Danenberg et al, Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as firstline therapy in patients with advanced or metastatic gastric cancer, Annals of Oncology 22 (2011), 2610-2615.
40. A. Italiano, P. Follana, FX. Caroli, JL. Badetti, D. Benchimol, G. Garnier et al, Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number, Annals of Surgical Oncology 15 (2008), 649-654.
41. A. Jahangiri, M.K. Aghi, Biomarkers predicting tumor response and evasion to anti-angiogenic therapy, Biochimica and Biophysica Acta 1825 (2012), 86-100.
42. R.K. Jain, D.G. Duda, C.G. Willett, D.V. Sahani, A.X. Zhu, J.S. Loeffler et al, Biomarkers of response and resistance to antiangiogenic therapy, Nature Reviews Clinical Oncology 6 (2009), 327-338.
43. S. Juttner, C. Wissmann, T. Jons, M. Vieth, J. Hertel, S. Gretsche et al, Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma, Journal of Clinical Oncology 24(2) (2006), 228-240.
44. S.E. Kern, E.R. Fearon, K.W. Tersmette, J.P. Enterline, M. Leppert, Y. Nakamura et al, Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected] The Journal of the American Medical Association 261(21) (1989), 3099-3103.
45. G.P. Kim, L.H. Colangelo, H.S. Wieand, S. Paik, M.J. O'Connell, I.R. Kirsch et al, Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a Nationa Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study, Journal of Clinical Oncology 25(7) (2007), 767-772.
46. S.H. Kim, K.H. Park, S.J. Shin, K.Y. Lee, T.I. Kim, N.K. Kim et al, P16 (INK4A) gene hypermethylation and kras mutation are independent predictors of FOLFIRI and cetuximab chemotherapy in patients with metastatic colorectal cancer (MCRC), Annals of Oncology 23 (Supplement 9) (2012) doi:10.1093/annonc/mds397.
47. S.D. Kirley, M. D'Apuzzo, G.Y. Lauwers, F. Graeme-Cook, D.C. Chung, LR. Zukerberg, The cables gene on chromosome 18Q regulates colon cancer progression in vivo, Cancer Biology & Therapy 4(8) (2005), 861-863.
48. A. Koutras, A. Antonacopoulou, F. Fostira, E.C. Briasoulis, I. Sgouros, A. Koumarianou et al, Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting, American Society of Clinical Oncology Annual Meeting, Chicago, IL (2010).
49. Y. Krupitskaya, H.A. Wakelee, Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer, Current Opinion in Investigational Drugs 10 (2009), 597-605.
50. D. Lambrechts, B. Claes, P. Delmar, J. Reumers, M. Mazzone, B.T. Yesilyurt et al, VEGFpathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials, Lancet Oncology 13 (2012), 724-733.
51. C. Lemech, J. Infante, HT. Arkenau, The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence, Therapeutic Advances in Medical Oncology 4(2) (2012), 61-73.
52. E. Lieto, F. Ferraraccio, M. Orditura, P. Castellano, A.L. Mura, M. Pinto et al, Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients, Annals of Surgical Oncology 15(1) (2008), 69-79.
53. F. Loupakis, C. Cremolini, A. Fioravanti, P. Orlandi, L. Salvatore, G. Masi et al, Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer, British Journal of Cancer 104 (2011), 1262-1269.
54. F. Loupakis, A. Falcone, G. Masi, A. Fioravanti, R.S. Kerbel, M. Del Tacca et al, Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity, Journal of Clinical Oncology 25 (2007), 1816-1818.
55. Y. Matsui, M. Inomata, M. Tojigamori, K. Sonoda, N. Shiraishi, S. Kitano, Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a urine model, International Journal of Oncology 27 (2005), 681-685.
56. M. Moehler, A. Mueller, J.T. Hartmann, M.P. Ebert, S.E. Al-Batran, P. Reimer et al, An open-label, multicentre biomarkeroriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer, European Journal of Cancer 47 (2011), 1511-1520.
57. J. Montomoli, S.J. Hamilton-Dutoit, T. Frøslev, A. Taylor, R. Erichsen, Retrospective analysis of KRAS status in metastatic colorectal cancer patients: A single-center feasibility study, Clinical and Experimental Gastroenterology 5 (2012), 167-171.
58. M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-Bianchi, F. Di Nicolantonio et al, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: A cohort study, Lancet Oncology 6 (2005), 279-286.
59. A.J. Munro, S. Lain, D.P. Lane, P53 abnormalities and outcomes in colorectal cancer: A systematic review, British Journal of Cancer 92(3) (2005), 434-444.
60. NCCN clinical practice colon cancer guidelines in oncology. Version 1.2013. NCCN.org.
61. M. Offterdinger, C. Schöfer, K. Weipoltshammer, T.W. Grunt, C-erbB-3: A nuclear protein in mammary epithelial cells, The Journal of Cell Biology 157 (2002), 929-939.
62. B.Y. Oh, R.A. Lee, S.S. Chung, K.H. Kim, Epidermal growth factor receptor mutations in colorectal cancer patients, Journal of the Korean Society of Coloproctology 27 (2011), 127-132.
63. A. Ohtsu, M.A. Shah, E. Van Cutsem, S.Y. Rha, A. Sawaki, S.R. Park et al, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study, Journal of Clinical Oncology 29(30) (2011), 3968-3976.
64. Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00096278?order=1.
65. J.H. Park, S.W. Han, D.Y. Oh, S.A. Im, S.Y. Jeong, K.J. Park et al, Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer, Cancer Chemotherapy and Pharmacology 68(4) (2011), 1045-1055.
66. M. Peeters, TJ. Price, A. Cervantes, AF. Sobrero, M. Ducreux, Y. Hotko et al, Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer, Journal of Clinical Oncology 28 (2010), 4706-4713.
67. D. Ribatti, G. Ranieri, A. Basile, A. Azzariti, A. Paradiso, A. Vacca, Tumor endothelial markers as a target in cancer, Expert Opinion on Therapeutic Targets (2012), [Epub ahead of print] PubMed PMID: 22978444.
68. C.M. Ribic, D.J. Sargent, M.J. Moore, S.N. Thibodeau, A.J. French, R.M. Goldberg et al, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil based adjuvant chemotherapy for colon cancer, The New England Journal of Medicine 349(3) (2003), 247-257.
69. S. Rizzo, G. Bronte, D. Fanale, L. Corsini, N. Silvestris, D. Santini et al, Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treatment Reviews 36(Suppl 3) (2010), 56-61.
70. E.K. Rowinsky, Signal events: Cell signal transduction and its inhibition in cancer, Oncologist 8 (Suppl. 3) (2003), 5-17.
71. D.W. Rusnak, K. Lackey, K. Affleck, E.R. Wood, K.J. Alligood, N. Rhodes et al, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo, Molecular Cancer Therapeutics 1 (2001), 85-94.
72. D. Santini, C. Spoto, F. Loupakis, B. Vincenzi, N. Silvestris, C. Cremolini et al, High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice, Annals of Oncology 21(7) (2010), 1565.
73. D.J. Sargent, S. Marsoni, G. Monges, S.N. Thibodeau, R. Labianca, S.R. Hamilton et al, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, Journal of Clinical Oncology 28(20) (2010), 3219-3226.
74. A. Sartore-Bianchi, F. Di Nicolantonio, M. Nichelatti, F. Molinari, S. De Dosso, P. Saletti et al, Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer, PLoS One 4(10) (2009), e728743.
75. T. Satoh, Y. Bang, J. Wang et al, Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer, Journal of Clinical Oncology 28 (2010), (Abstract 4057).
76. T. Satoh, Y. Yamada, K. Muro, H. Hayashi, Y. Shimada, D. Takahari et al, Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gas tric cancer, Cancer Chemotherapy and Pharmacology 69(2) (2011), 439-446.
77. N.V. Sergina, M. Rausch, D. Wang, J. Blair, B. Hann, K.M. Shokat et al, Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3, Nature 445 (2007), 437-441.
78. R. Seth, S. Crook, S. Ibrahem, W. Fadhil, D. Jackson, M. Ilyas, Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer, Gut 58(9) (2009), 1234-1241.
79. M.A. Shah, R.K. Ramanathan, D.H. Ilson, A. Levnor, D. D'Adamo, E. O'Reilly et al, Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma, Journal of Clinical Oncology 24(33) (2006), 5201-5206.
80. H.M. Shepard, C.M. Brdlik, H. Schreiber, Signal integration: A framework for understanding the efficacy of therapeutics targeting the human EGFR family, The Journal of Clinical Investigation 118 (2008), 3574-3581.
81. N. Silvestris, A. Azzariti, L. Porcelli, A.E. Quatrale, A. Paradiso, G. Colucci, Possible role of vascular endothelial growth factor (VEGF) levels in immunodepleted plasma of metastatic colorectal cancer (mCRC) patients (pts) treated with a biweekly administration of capecitabine plus oxaliplatin (XELOX-2) plus bevacizumab: Preliminary results, American Society of Clinical Oncology Annual Meeting, Chicago, IL (2010).
82. N. Silvestris, S. Tommasi, D. Petriella, D. Santini, E. Fistola, A. Russo et al, The Dark Side of the Moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma, Oncology 77(suppl 1) (2009), 69-74.
83. N. Silvestris, S. Tommasi, D. Santini, A. Russo, G. Simone, D. Petriella et al, KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue, Expert Opinion on Therapeutic Patents 9(5) (2009), 565-577.
84. W. Sun, Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy, Journal of Hematology & Oncology 5 (2012), 63.
85. rd, Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203, Journal of Clinical Oncology 28 (2010), 2947-2951.
86. M. Tanner, M. Hollmen, T.T. Junttila, A.I. Kapanen, S. Tommola, Y. Soini et al, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab, Annals of Oncology 16 (2005), 273-278.
87. S. Tejpar, I. Celik, M. Schlichting, U. Sartorius, C. Bokemeyer, E. Van Cutsem, Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab, Journal of Clinical Oncology 30 (29) (2012), 3570-3577.
88. N. Tzanakis, M. Gazouli, G. Rallis, G. Giannopoulos, I. Papaconstantinou, G. Theodoropoulos, et al, Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival, Journal of Surgical Oncology 94(7) (2006), 624-630.
89. E. Van Cutsem, I. Lang, G. D'haens, V. Moiseyenko, J. Zaluski, C. Kohne et al, The crystal study: assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first-line treatment with cetuximab or cetuximab plus folfiri [Abstract], Annals of Oncology 19(Suppl 6) (2008), vi17-8.
90. S.C. Wang, H.C. Lien, W. Xia, I.F. Chen, H.W. Lo, Z. Wang et al, Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2, Cancer Cell 6 (2004), 251-261.
91. T. Watanabe, T.T. Wu, P.J. Catalano, T. Ueki, R. Satriano, DG. Haller et al, Molecular predictors of survival after adjuvant chemotherapy for colon cancer, The New England Journal of Medicine 344(16) (2001), 1196-1206.
92. C.G. Willett, Y. Boucher, D.G. Duda, E. di Tomaso, L.L. Munn, R.T. Tong et al, Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients, Journal of Clinical Oncology 23 (2005), 8136-8139.
93. C.G. Willett, D.G. Duda, E. di Tomaso, Y. Boucher, M. Ancukiewicz, D.V. Sahani et al, Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study, Journal of Clinical Oncology 27 (2009), 3020-3026.
94. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian et al, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, The New England Journal of Medicine 349 (2003), 427-434.
95. Z.Y. Yang, W.X. Shen, X.F. Hu, D.Y. Zheng, X.Y. Wu, Y.F. Huang et al, EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: A meta-analysis, Journal of Hematology & Oncology 5 (2012), 52.
96. Y. Yonemura, I. Ninomiya, A. Yamaguchi, S. Fushida, H. Kimura, S. Ohoyama, et al, Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer, Cancer Research 51 (1991), 1034-1038.